UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). It has received authorisation as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. The approval was based on safety and efficacy data from a global, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!